Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
Part of paid clinical trials in Buffalo, New York.
- Sponsor
- Universiteit Leiden
- Study ID
- NCT07225868
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Conscientiousness Coaching Before Cognitive Rehabilitation — BEHAVIORALIn this arm, participants complete the conscientiousness coaching before the cognitive rehabilitation. All participants (both arms) will receive 6 weeks of cognitive rehabilitation using BrainHQ (2 times per week, 1 hour each).
- Sham Intervention Before Cognitive Rehabilitation — BEHAVIORALIn this arm, participants complete the sham intervention before the cognitive rehabilitation. All participants (both arms) will receive 6 weeks of cognitive rehabilitation using BrainHQ (2 times per week, 1 hour each).
Study Details
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Key Dates
- Start date
- Nov 1, 2025
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 126 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Conscientiousness Coaching
- Sham Comparator: Sham Intervention
Primary Outcome Measure
Objective cognitive changes between baseline and post-intervention [ Time Frame: Between baseline and week 18. ]
Central Contacts
- Charlotte C Rouzee, MSc062 831 93 32
- Marit FL Ruitenberg, PhD071 527 2727
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo | Buffalo | New York | 14203 | Ralph HB Benedict, Prof (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Buffalo, NY
Related Studies
- Genes and Environment in Multiple SclerosisRecruiting · Columbia University · Bethesda, Maryland
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- Vancomycin Study in Multiple Sclerosis (MS)PHASE1 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York